Delayed urticaria after BNT162b2 booster vaccination at previous intradermal test site with severe acute respiratory syndrome-coronavirus-2 spike protein

Urticaria is a common cutaneous adverse event from coronavirus disease 2019 vaccination. Previous studies hypothesized that excipients as polyethylene glycol in BNT162b2 vaccine and polysorbate in ChAdOx1 nCoV-19 vaccine are allergens. A 28-year-old woman had urticaria after a booster vaccination wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Triwatcharikorn, Jidapa, Klaewsongkram, Jettanong, Rerknimitr, Pawinee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asia Pacific Association of Allergy, Asthma and Clinical Immunology 2022
Materias:
Hypothesis & Experience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353207/
https://www.ncbi.nlm.nih.gov/pubmed/35966159
http://dx.doi.org/10.5415/apallergy.2022.12.e27
Descripción
Sumario:Urticaria is a common cutaneous adverse event from coronavirus disease 2019 vaccination. Previous studies hypothesized that excipients as polyethylene glycol in BNT162b2 vaccine and polysorbate in ChAdOx1 nCoV-19 vaccine are allergens. A 28-year-old woman had urticaria after a booster vaccination with BNT162b2 at the site of previous intradermal injection with severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) spike protein. This reaction emphasized that delayed urticaria may not be an allergic reaction to excipient but rather to the immunogen as such as SARS-CoV-2 spike protein.

Ejemplares similares